Prostate cancer risk-associated genetic markers and their potential clinical utility

Asian Journal of Andrology

Volumn 15, Issue 3, 2013, Pages 314-322

  Xu, Jianfeng ^a,b,c,d   Sun, Jielin ^d   Zheng, S Lilly ^d  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Biopsy; Chinese; Family history; Genetic score; Heritability; Prostate cancer (PCa); Prostate specific antigen (PSA); PSA screen; Single nucleotide polymorphisms (SNPs)

Indexed keywords

CANCER INCIDENCE; CANCER RISK; FAMILY HISTORY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84877277468     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2013.42     Document Type: Review

References (106)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Cullen J, Elsamanoudi S, Brassell SA, Chen Y, Colombo Met al. The burden of prostate cancer in Asian nations. J Carcinog 2012; 11: 7.
4. Woolf CM. An investigation of the familial aspects of carcinoma of the prostate. Cancer 1960; 13: 739-44.
5. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003; 91: 789-94.
6. Goh CL, Schumacher FR, Easton D, Muir K, Henderson B et al. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med 2012; 271: 353-65.
7. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-34.
8. Thomas JA 2nd, Gerber L, Moreira DM, Hamilton RJ, Bañez LL et al. Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). J Intern Med 2012; 272: 85-92.
9. Chen YC, Page JH, Chen R, Giovannucci E. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate 2008; 68: 1582-91.
10. Ahn J, Moslehi R, Weinstein SJ, Snyder K, Virtamo J et al. Family history of prostate cancer and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Int J Cancer 2008; 123: 1154-9.
11. Page WF, Braun MM, Partin AW, Caporaso N, Walsh P. Heredity and prostate cancer: A study of World War II veteran twins. Prostate 1997; 33: 240-5.
12. Ahlbom A, Lichtenstein P, Malmström H, Feychting M, Hemminki K et al. Cancer in twins: genetic and nongenetic familial risk factors. J Natl Cancer Inst 1997; 89: 287-93.
13. Verkasalo PK, Kaprio J, Koskenvuo M, Pukkala E. Genetic predisposition, environment and cancer incidence: A nationwide twin study in Finland, 1976-1995. Int J Cancer 1999; 83: 743-9.
14. Neale RE, Mineau G, Whiteman DC, Brownbill PA, Murphy MF. Childhood and adult cancer in twins: evidence from the Utah genealogy. Cancer Epidemiol Biomarkers Prev 2005; 14: 1236-40.
15. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
16. Carter BS, Steinberg GD, Beaty TH, Childs B, Walsh PC. Familial risk factors for prostate cancer. Cancer Surv 1991; 11: 5-13.
17. Grönberg H, Damber L, Damber JE, Iselius L. Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol 1997; 146: 552-7.
18. Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998; 62: 1425-38.
19. Verhage BA, Baffoe-Bonnie AB, Baglietto L, Smith DS, Bailey-Wilson JE et al. Autosomal dominant inheritance of prostate cancer: A confirmatory study. Urology 2001; 57: 97-101.
20. Gong G, Oakley-Girvan I, Wu AH, Kolonel LN, John EM et al. Segregation analysis of prostate cancer in 1,719 white, African-American and Asian-American families in the United States and Canada. Cancer Causes Control 2002; 13: 471-82.
21. Baffoe-Bonnie AB, Kiemeney LA, Beaty TH, Bailey-Wilson JE, Schnell AH et al. Segregation analysis of 389 Icelandic pedigrees with Breast and prostate cancer. Genet Epidemiol 2002; 23: 349-63.
22. Valeri A, Briollais L, Azzouzi R, Fournier G, Mangin P et al. Segregation analysis of prostate cancer in France: evidence for autosomal dominant inheritance and residual brother-brother dependence. Ann Hum Genet 2003; 67(Pt 2)125-37.
23. Conlon EM, Goode EL, Gibbs M, Stanford JL, Badzioch Met al. Oligogenic segregation analysis of hereditary prostate cancer pedigrees: evidence for multiple loci affecting age at onset. Int J Cancer 2003; 105: 630-5.
24. Pakkanen S, Baffoe-Bonnie AB, Matikainen MP, Koivisto PA, Tammela TL et al. Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance. Hum Genet 2007; 121: 257-67.
25. Mac Innis RJ, Antoniou AC, Eeles RA, Severi G, Guy M et al. Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies. Genet Epidemiol 2010; 34: 42-50.
26. Smith JR, Freije D, Carpten JD, Grönberg H, Xu J et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371-4.
27. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002; 30: 181-4.
28. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001; 27: 172-80.
29. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002; 32: 321-5.
30. Xu J, Meyers D, Freije D, Isaacs S, Wiley K et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998; 20: 175-9.
31. Edwards S, Meitz J, Eles R, Evans C, Easton D et al. Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. Prostate 2003; 57: 270-9.
32. Schleutker J, Baffoe-Bonnie AB, Gillanders E, Kainu T, Jones MP et al. Genome-wide scan for linkage in Finnish hereditary prostate cancer (HPC) families identifies novel susceptibility loci at 11q14 and 3p25-26. Prostate 2003; 57: 280-9.
33. Wiklund F, Gillanders EM, Albertus JA, Bergh A, Damber JE et al. Genome-wide scan of Swedish families with hereditary prostate cancer: suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate 2003; 57: 290-7.
34. Lange EM, Gillanders EM, Davis CC, Brown WM, Campbell JK et al. Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. Prostate 2003; 57: 326-34.
35. Friedrichsen DM, Stanford JL, Isaacs SD, Janer M, Chang BL et al. Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. Proc Natl Acad Sci USA 2004; 101: 1939-44.
36. Gillanders EM, Xu J, Chang BL, Lange EM, Wiklund F et al. Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst 2004; 96: 1240-7.
37. Camp NJ, Farnham JM, Cannon Albright LA. Genomic search for prostate cancer predisposition loci in Utah pedigrees. Prostate 2005; 65: 365-74.
38. Chang BL, Isaacs SD, Wiley KE, Gillanders EM, Zheng SL et al. Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease. Prostate 2005; 64: 356-61.
39. Slager SL, Zarfas KE, Brown WM, Lange EM, McDonnell SK et al. Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate 2006; 66: 173-9.
40. Lange EM, Ho LA, Beebe-Dimmer JL, Wang Y, Gillanders EM et al. Genome-wide linkage scan for prostate cancer susceptibility genes in men with aggressive disease: significant evidence for linkage at chromosome 15q12. Hum Genet 2006; 119: 400-7.
41. Christensen GB, Camp NJ, Farnham JM, Cannon-Albright LA. Genome-wide linkage analysis for aggressive prostate cancer in Utah high-risk pedigrees. Prostate 2007; 67: 605-13.
42. Schaid DJ, Stanford JL, McDonnell SK, Suuriniemi M, McIntosh L et al. Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q. Hum Genet 2007; 121: 729-35.
43. Baffoe-Bonnie AB, Kittles RA, Gillanders E, Ou L, George A et al. Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer study (AAHPC). Prostate 2007; 67: 22-31.
44. Stanford JL, Fitz Gerald LM, McDonnell SK, Carlson EE, McIntosh LM et al. Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Hum Mol Genet 2009; 18: 1839-48.
45. Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR et al. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics.Am J Hum Genet 2005; 77: 219-29.
46. Schaid DJ, McDonnell SK, Zarfas KE, Cunningham JM, Hebbring S et al. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet 2006; 120: 471-85.
47. Camp NJ, Cannon-Albright LA, Farnham JM, Baffoe-Bonnie AB, George A et al. Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet 2007; 16: 1271-8.
48. Christensen GB, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE et al. Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sum LINK and sum LOD analyses. Prostate 2010; 70: 735-44.
49. Lu L, Cancel-Tassin G, Valeri A, Cussenot O, Lange EM et al. Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. Prostate 2012; 72: 410-26.
50. Bailey-Wilson JE, Childs EJ, Cropp CD, Schaid DJ, Xu J et al. Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. BMC Med Genet 2012; 13: 46.
51. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012; 366: 141-9.
52. Breyer JP, Avritt TG, McReynolds KM, Dupont WD, Smith Jr. Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2012; 21: 1348-53.
53. Akbari MR, Trachtenberg J, Lee J, Tam S, Bristow R et al. Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst 2012; 104: 1260-2.
54. Karlsson R, Aly M, Clements M, Zheng L, Adolfsson J et al. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol; e-pub ahead of print 20 July 2012.
55. Schroeck FR, Zuhlke KA, Siddiqui J, Siddiqui R, Cooney KA et al. Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy. J Urol 2013; 189: 849-53.
56. Xu J, Lange EM, Lu L, Zheng SL, Wang Z et al. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 2013; 132: 5-14.
57. Gudmundsson J, Sulem P, Gudbjartsson DF, Masson G, Agnarsson BA et al. A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet 2012; 44: 1326-9.
58. Stott-Miller M, Karyadi DM, Smith T, Kwon EM, Kolb S et al. HOXB13 mutations in a population-based, case-control study of prostate cancer. Prostate; e-pub ahead of print 5 November 2012; doi: 10.1002/pros.22604.
59. Laitinen VH, Wahlfors T, Saaristo L, Rantapero T, Pelttari LM et al. HOXB13 G84E mutation in Finland; population-based analysis of prostate, breast and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2013; 22: 452-60.
60. Kluźniak W, Wokoorczyk D, Kashyap A, Jakubowska A, Gronwald J et al. The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. Prostate 2013; 73: 542-8.
61. Chen Z, Greenwood C, Isaacs WB, Foulkes WD, Sun J et al. The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial. Carcinogenesis; e-pub ahead of print 11 March 2013.
62. Lin X, Qu L, Chen Z, Xu C, Ye D et al. A novel Germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate 2013; 73: 169-75.
63. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 4: 45-61.
64. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38: 652-8.
65. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-9.
66. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 2009; 106: 9362-7.
67. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39: 645-9.
68. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39: 631-7.
69. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977-83.
70. Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99: 1836-44.
71. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-5.
72. Eeles RA, Kote-Jarai Z, Giles GG, Al Olama AA, Guy M et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40: 316-21.
73. Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008; 40: 281-3.
74. Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1058-60.
75. Yeager M, Chatterjee N, Ciampa J, Jacobs KB, Gonzalez-Bosquet J et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet 2009; 41: 1055-7.
76. Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy Met al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009; 41: 1116-21.
77. Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason A et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1122-6.
78. Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 2011; 20: 3867-75.
79. Kote-Jarai Z, Al Olama AA, Leongamornlert D, Tymrakiewicz M, Saunders E et al. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet 2011; 129: 687-94.
80. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 2011; 43: 570-3.
81. Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 2010; 42: 751-4.
82. Akamatsu S, Takata R, Haiman CA, Takahashi A, Inoue T et al. Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet 2012; 44: 426-9, S1.
83. Xu J, Mo Z, Ye D, Wang M, Liu F et al. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet 2012; 44: 1231-5.
84. Zheng SL, Stevens VL, Wiklund F, Isaacs SD, Sun J et al. Two independent prostate cancer risk-associated Loci at 11q13. Cancer Epidemiol Biomarkers Prev 2009; 18: 1815-20.
85. Sun J, Zheng SL, Wiklund F, Isaacs SD, Purcell LD et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008; 40: 1153-5.
86. Hsu FC, Sun J, Wiklund F, Isaacs SD, Wiley KE et al. A novel prostate cancer susceptibility locus at 19q13. Cancer Res 2009; 69: 2720-3.
87. Sun J, Zheng SL, Wiklund F, Isaacs SD, Li G et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res 2009; 69: 10-5.
88. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910-9.
89. Xu J, Sun J, Kader AK, Lindström S, Wiklund F et al. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 2009; 69: 1565-72.
90. Salinas CA, Koopmeiners JS, Kwon EM, Fitz Gerald L, Lin DW et al. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 2009; 69: 363-72.
91. Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 2008; 17: 2052-61.
92. Sun J, Kader AK, Hsu FC, Kim ST, Zhu Y et al. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate 2011; 71: 421-30.
93. Lindström S, Schumacher FR, Cox D, Travis RC, Albanes D et al. Common genetic variants in prostate cancer risk prediction - results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 2012; 21: 437-44.
94. Klein RJ, Hallden C, Gupta A, Savage CJ, Dahlin A et al. Evaluation of multiple riskassociated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol 2012; 61: 471-7.
95. Akamatsu S, Takahashi A, Takata R, Kubo M, Inoue T et al. Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese. PLo S One 2012; 7: e46454.
96. Zheng J, Liu F, Lin X, Wang X, Ding Q et al. Predictive performance of prostate cancer risk in Chinese men using reported prostate cancer risk-associated SNPs. Prostate 2012; 72: 577-83.
97. Aly M, Wiklund F, Xu J, Isaacs WB, Eklund M et al. Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol 2011; 60: 21-8.
98. Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST et al. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol 2012; 62: 953-61.
99. Jiang H, Liu F, Wang Z, Na R, Zhang L et al. Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer riskassociated SNPs. Prostate 2013; In press.
100. Andriole GA, Bostwick D, Brawley OW, Gomella LG, Marberger M et al. The influence of dutasteride on the risk of biopsy-detectable prostate cancer: outcomes of the REduction by DUtasteride of Prostate Cancer Events (REDUCE) study. N Engl J Med 2010; 362: 1192-202.
101. Liu F, Hsing AW, Wang X, Shao Q, Qi J et al. Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men. Cancer Sci 2011; 102: 1916-20.
102. Wang M, Liu F, Hsing AW, Wang X, Shao Q et al. Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: A case-control study in the China PCa consortium. Carcinogenesis 2012; 33: 356-60.
103. Na R, Liu F, Zhang P, Ye D, Xu C et al. Evaluation of reported prostate cancer riskassociated SNPs from genome-wide association studies of various racial populations in Chinese men. Prostate 2013; In press.
104. Turner AR, Kader AK, Xu J. Utility of genome-wide association study findings: prostate cancer as a translational research paradigm. J Intern Med 2012; 271: 344-52.
105. Kader AK, Xu J. Reply from Authors re: Matthew R. Cooperberg. Will biomarkers save prostate cancer screening? Eur Urol 2012; 62: 962-3.
106. Sun J, Na R, Hsu FC, Zheng SL, Wiklund F et al. Genetic score is an objective and better measurement of inherited risk of prostate cancer than family history. Eur Urol 2013; 63: 585-7.